Randomized, Comparative, Clinical Trial to Evaluate Efficacy and Safety of PNB-001 in Moderate COVID-19 Patients
Randomized, comparative clinical trial evaluating the efficacy and safety of PNB-001 in moderate COVID-19 patients.
HomePublications
Scientific publications and research outputs associated with PNB Vesper's development programmes.
Human trial reports for PNB-001, the lead molecule.
Randomized, comparative clinical trial evaluating the efficacy and safety of PNB-001 in moderate COVID-19 patients.
Randomized, comparative clinical trial evaluating PNB-001 as an immune modulator in moderate COVID-19 patients.
The document shared on ResearchGate for the same PNB-001 trial in moderate COVID-19.
Preclinical studies of CCK receptor antagonists in colon, pancreatic, lung and Brain Cancer.
Listed as a second entry under the same title, with its own file, on the previous website.
CCK-2/gastrin antagonists as anti-inflammatory analgesics, and as an adjunct to opiates.
No file was attached to this entry on the previous website; the article is available from the publisher.
Where the chemistry started, and the preclinical work that led to the first human trial.
Two peer-reviewed papers on CCK-A (CCK-1) receptor antagonists in colon and Pancreatic Cancer, as published in international journals.
[4] Oncology Reports 35: 2097–2106, 2016
PNB-028 Colon and Pancreatic Cancer
Download the full paperPDF: Novel, isoform-selective, cholecystokinin A receptor antagonist inhibits colon and pancreatic cancers in preclinical models through novel mechanism of action (opens in a new tab)Colon and pancreatic cancers contribute to 90,000 deaths each year in the USA. These cancers lack targeted therapeutics due to heterogeneity of the disease and multiple causative factors. One important factor that contributes to increased colon and Pancreatic Cancer risk is gastrin. Gastrin mediates its actions through two G-protein coupled receptors (GPCRs): cholecystokinin receptor A (CCK-A) and CCK-B/gastrin receptor. Previous studies have indicated that Colon Cancer predominantly expresses CCK-A and responds to CCK-A isoform antagonists. However, many CCK-A antagonists have failed in the clinic due to poor pharmacokinetic properties or lack of efficacy. In the present study, we synthesized a library of CCK-A isoform-selective antagonists and tested them in various colon and Pancreatic Cancer preclinical models. The lead CCK-A isoform, selective antagonist PNB-028, bound to CCK-A at 12 nM with a 60-fold selectivity towards CCK-A over CCK-B. Furthermore, it inhibited the proliferation of CCK-A-expressing colon and Pancreatic Cancer cells without affecting the proliferation of non-cancerous cells. PNB-028 was also extremely effective in inhibiting the growth of MAC-16 and LoVo Colon Cancer and MIA PaCa Pancreatic Cancer xenografts in immune-compromised mice. Genome-wide microarray and kinase-array studies indicate that PNB-028 inhibited oncogenic kinases and angiogenic factors to inhibit the growth of Colon Cancer xenografts. Safety pharmacology and toxicology studies have indicated that PNB-028 is extremely safe and has a wide safety margin. These studies suggest that targeting CCK-A selectively renders promise to treat colon and pancreatic cancers and that PNB-028 could become the next-generation treatment option.
[5] MedChemComm, United Kingdom, 2016
PNB-028 Colon and Pancreatic Cancer
Download the full paperPDF: Cholecystokinin-1 receptor antagonists: 5-hydroxy-5-aryl-pyrrol-2-ones as anticancer agents (opens in a new tab)A new class of 5-arylated 5-hydroxypyrrolones was derived from mucochloric acid in 2 synthetic steps and the chemical structure was confirmed additionally by x-ray analysis. Using a radiolabelled binding assay, potent CCK1 selective ligands were identified (CCK1: 12 nM) and the antagonism was confirmed by using isolated tissue preparations. A series of isobutyl derivatives displayed unsurmountable CCK antagonistic properties and in vitro excellent inhibition of proliferation was obtained in cholecystokinin related cancer cell lines in the nanomolar range. Finally, using xenograft studies in nude mice, two selected pyrrolone derivatives, X=H and X=F, a fluorinated analogue (PNB-028), showed a strong inhibition of tumour growth in a chemo-resistant Colon Cancer (MAC 16) and a human pancreatic cell line (MIAPACA) at 50 mg/kg by oral administration.
Summaries of every PNB-001 and PNB-028 trial, including Phase 1, Inflammatory Bowel Disease and Type 2 Diabetes, are on the clinical trials page.